Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

June 2022, just before the Fed started increasing rates, and is now 3% below that level, underperforming the broader markets, with the S&P 500 rising 16% over this per

Will Medtronic Stock Rebound To Its Pre-Inflation Shock Highs?

Exxon Mobil

Undervalued retirement stocks steal the spotlight when it comes to constructing a robust retirement portfolio. These stocks present opportunities for capital growth and offer a steady income stream through dividend payments.

The 3 Most Undervalued Retirement Stocks to Buy Now: June 2023

Arista Networks

Artificial intelligence has been billed as the next industrial revolution. Medtronic and Arista Networks are early adopters of the tech.

Better Artificial Intelligence Stock: Medtronic or Arista Networks?

Automatic Data Processing

Albemarle

Cincinnati Financial

Clorox

Essex Property Trust

Hormel Foods

Realty Income Corp

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

Walgreens

The ProShares S&P 500 Dividend Aristocrats ETF is recovering in June after a poor performance in May, with a 5.96% gain compared to a 5.90% loss in the previous month. Despite this, 31 dividend aristocrats are outperforming NOBL year-to-date through May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After nearly 23 months, 2 of the 3 buy-and-hold portfolios continue to generate alpha over NOBL and all 3 are beating SPY.

My Best Dividend Aristocrats For July 2023

Edison

McDonald's

Dividend stocks and income investing are back on everyone's radar in 2023. Safe mainstays like short-term Treasury Bills and high-yield savings accounting generate decent returns for the first in years.

3 Dividend Stocks With Massive Payout Ratios

Intuitive Surgical

There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer better returns than MDT stock in the next three years.

Should You Buy Intuitive Surgical Stock Over MDT?

Medtronic plc (NYSE:MDT ) Analyst and Investor Briefing Conference Call June 25, 2023 4:00 PM ET Company Participants Ryan Weispfenning - Vice President, Head of Investor Relations Geoff Martha - Chairman and Chief Executive Officer Que Dallara - Executive Vice President and President, Diabetes Ali Dianaty - Senior Vice President, Product Innovation and Operations, Diabetes Conference Call Participants Matt Miksic - Barclays Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Steve Lichtman - Oppenheimer Joanne Wuensch - Citibank Chris Pasquale - Nephron Jayson Bedford - Raymond James Matt Taylor - Jefferies Danielle Antalffy - UBS Matt O'Brien - Piper Sandler Travis Steed - Bank of America Anthony Petrone - Mizuho Jeff Johnson - Baird Marie Thibault - BTIG Ryan Weispfenning Okay. Good afternoon, everyone.

Medtronic plc (MDT) Analyst and Investor Briefing Conference - (Transcript)

Medtronic (MDT) presents the clinical and real-world data on the MiniMed 780G system at ADA Scientific Sessions in San Diego.

Medtronic's (MDT) MiniMed 780G System Favored by New Data

DUBLIN , June 26, 2023 /PRNewswire/ -- Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board. Lewis will serve on the Audit Committee and the Finance and Financial Risk Committee, effective June 26, 2023.

Medtronic Board appoints Greg Lewis as new Director

DUBLIN and SAN DIEGO , June 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection™ technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent.

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

UnitedHealth Group

Health care stocks to check out in the stock market today.

Top Health Care Stocks To Buy Today? 2 To Know

Stryker

The healthcare industry is facing pent-up demand for surgeries. Health insurers may struggle with some additional costs as a result.

Elective Surgeries Are On the Rise: 3 Stocks That Can Benefit From This Trend

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, today announced a pilot collaboration agreement with Medtronic, a global leader in healthcare technology, to expand access to Allurion's AI-powered weight loss program through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region. The partnership enables Allurion to offer the Allurion Balloon and accelerate utilization of the Allurion Iris Artificial Intelligence (AI) Pla.

Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program

Johnson & Johnson

The global AI-in-healthcare market is on track to top $100 billion later this decade. Companies that invest in the area now could reap the rewards down the road.

AI May Transform Healthcare: 2 Top Stocks to Buy Now

The company marked the 46th year of dividend increases, a trend unlikely to stop any time soon.

Top Dividend Stocks: Steady Medtronic Raises Dividend For 46th Straight Year

Over the last few decades, medical device company Medtronic has made long-term investors rich. Cannabis company Cresco Labs is working hard to reduce costs and turn a profit.

2 Promising Stocks That Are Screaming Buys in June

Medtronic is weighing its next steps after losing another round in a long-running patent dispute with med-tech competitor Teleflex Inc.

Medtronic weighs appeal after losing patent case regarding catheter technology

SkyQuest's ENT Devices market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is produced and published concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections. SkyQuest's ENT Devices market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is produced and published concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections.

ENT Devices Market Size to Grow Higher by 2030

A recent trend in the U.S. healthcare system could strongly benefit the medical device segment. The health care system is now addressing pent-up demand for procedures that were postponed during the hotter periods of the pandemic.

Why Medical Device Stocks Like Medtronic Were So Healthy Today

Charles River Laboratories

One of the greatest changes in the American landscape going forward will be demographics. The Baby Boomers make up the largest generation in the country's history.

3 Long-term Healthcare Stocks to Add to Your Portfolio

MDT, a member of the S&P Dividend Aristocrats index, recently provided weak guidance which dampens its low-dividend cover even more. We still appreciate some of the other dividend sub-plots. We shed some insight into the technical and valuation developments.

Is Medtronic's Dividend In A Good Place?

Medtronic plc (NYSE:MDT ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 12, 2023 1:40 PM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Conference Call Participants Jamie Perse - Goldman Sachs Jamie Perse All right. Good morning, everyone.

Medtronic plc (MDT) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

DUBLIN , June 12, 2023 /PRNewswire/ -- Medtronic plc  (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association's (ADA) 83rd Scientific Sessions in San Diego on Jun. 23-26, 2023. During the conference, Medtronic will present new data and clinical outcomes across a broad population of patients from its newly FDA-approved MiniMed™ 780G system with Guardian™ 4 sensor — which began shipping in the U.S. earlier this month — as well as their Extended Infusion Set and InPen™ smart insulin pen.

Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions

Amazon

Moderna

AI stocks don't necessarily have to be technology companies. Some e-commerce and healthcare companies are investing in AI -- this can benefit their businesses and investors over time.

3 Top AI Stocks to Buy Hand Over Fist

Lowe's

Medtronic and Lowe's have both increased their dividend payments for more than 40 consecutive years. Medtronic expects new product launches, and it is also seeing a recovery in the volume of procedures.

News for Medtronic Stock (MDT)